Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

2.170 -0.090 (-3.98%)
Streaming Delayed Price Updated: 10:50 AM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,441
Open 2.260
Bid (Size) 2.160 (2)
Ask (Size) 2.170 (1)
Prev. Close 2.260
Today's Range 2.150 - 2.260
52wk Range 1.000 - 6.600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga

Performance

YTD
-41.5%
-41.5%
1 Month
+23.6%
+23.6%
3 Month
+27.6%
+27.6%
6 Month
-2.7%
-2.7%
1 Year
-19.6%
-19.6%

More News

Read More
SAB BIO Announces Oversubscribed $175 Million Private Placement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Is SAB BIO Stock Trading Lower On Tuesday?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Reports Full Year 2024 Operating and Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
Via Benzinga
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
Via Benzinga
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
Via Benzinga
Topics Stocks
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024
Via InvestorPlace
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
SAB BIO Appoints Lucy To as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is SAB Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, SAB Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does SAB Biotherapeutics, Inc. - Common Stock trade on?
SAB Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for SAB Biotherapeutics, Inc. - Common Stock?
The ticker symbol for SAB Biotherapeutics, Inc. - Common Stock is SABS on the Nasdaq Stock Market
What is the current price of SAB Biotherapeutics, Inc. - Common Stock?
The current price of SAB Biotherapeutics, Inc. - Common Stock is 2.170
When was SAB Biotherapeutics, Inc. - Common Stock last traded?
The last trade of SAB Biotherapeutics, Inc. - Common Stock was at 07/31/25 10:50 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS